Autori: Andric Zoran G
Naslov | Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study. (Meeting Abstract) |
Autori | Millan Susana Trukhin Dmytro Kolesnik Oleksii Poddubskaya Elena Andric Zoran G ![]() |
Info | JOURNAL OF CLINICAL ONCOLOGY, (2020), vol. 38 br. 15, Suppl. S, str. - |
Projekat | mAbxience Research SI |
Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
|
Naslov | Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer. (Meeting Abstract) |
Autori | Jared Weiss Jerome Goldschmidt Andric Zoran G ![]() |
Info | JOURNAL OF CLINICAL ONCOLOGY, (2020), vol. 38 br. 15, Suppl. S, str. - |
Projekat | G1 Therapeutics, Inc. |
Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science Scopus |
|
Naslov | Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC (Meeting Abstract) |
Autori | Herbst Roy S ... Andric Zoran G ![]() |
Info | JOURNAL FOR IMMUNOTHERAPY OF CANCER, (2020), vol. 8 br. , Suppl. 1, str. A1-A1 |
Ispravka | Web of Science Članak Elečas Rang časopisa Citati: Web of Science |
|
Naslov | Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC (Meeting Abstract) |
Autori | Reinmuth Niels ... Andric Zoran G ![]() |
Info | ONCOLOGY RESEARCH AND TREATMENT, (2020), vol. 43 br. , Suppl. 1, str. 232-233 |
Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
|
Naslov | Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial (Article) |
Autori | Mansfield AS ... Andric Zoran G ![]() |
Info | ANNALS OF ONCOLOGY, (2020), vol. 31 br. 2, str. 310-317 |
Projekat | F. Hoffmann-La Roche Ltd, Basel, SwitzerlandHoffmann-La Roche |
Ispravka | Web of Science Članak Elečas Rang časopisa Citati: Web of Science Scopus |
|
Naslov | Relationship between distribution of LDL subfractions and NAFLD in PCOS - Effect on CV risk (Meeting Abstract) |
Autori | Perovic-Blagojevic Iva M Ignjatovic Svetlana D ![]() ![]() ![]() ![]() |
Info | CLINICA CHIMICA ACTA, (2019), vol. 493 br. , Suppl. 1, str. S340-S340 |
Ispravka | Web of Science Članak Elečas Rang časopisa Citati: Web of Science |
|
Naslov | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study (Meeting Abstract) |
Autori | Herbst Roy S ... Andric Zoran G ![]() |
Info | ANNALS OF ONCOLOGY, (2019), vol. 30 br. , Suppl. 11, str. 62-63 |
Projekat | F. Hoffmann-La RocheHoffmann-La Roche |
Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
|
Naslov | Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22 (Meeting Abstract) |
Autori | Siefker-Radtke Arlene O Lugowska Iwona Tupikowski Krzysztof Andric Zoran G ![]() |
Info | ANNALS OF ONCOLOGY, (2019), vol. 30 br. , Suppl. 5, str. 365-365 |
Projekat | Rainier Therapeutics, Inc. |
Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
|
Naslov | IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC (Meeting Abstract) |
Autori | Spigel David R ... Andric Zoran G ![]() |
Info | ANNALS OF ONCOLOGY, (2019), vol. 30 br. , Suppl. 5, str. 915-915 |
Projekat | F. Hoffmann-La RocheHoffmann-La Roche |
Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
|
Naslov | Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. (Meeting Abstract) |
Autori | Hart Lowell L Andric Zoran G ![]() ![]() |
Info | JOURNAL OF CLINICAL ONCOLOGY, (2019), vol. 37 br. 15, Suppl. S, str. - |
Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
|